Today
-1.75%
5 Days
-2.09%
1 Month
+0.88%
6 Months
-11.30%
Year to Date
+2.45%
1 Year
+19.81%
• McKesson shares declined following margin contraction in the U.S. Pharmaceutical segment. • Management maintained full-year earnings guidance, disappointing investors seeking an upward revision. • Regulatory scrutiny regarding drug pricing and reimbursement creates significant uncertainty for the firm.
• McKesson reported fiscal first-quarter earnings exceeding consensus expectations across core metrics. • Management raised full-year earnings guidance, citing strength in oncology and biopharma services. • The company leads its industry with $403.43 billion in latest annual revenue.
• Novo Nordisk's share price fell due to competition and sales outlook concerns. • Eli Lilly's GLP-1 products intensify competition for Novo Nordisk. • U.S. pricing pressures and sales contraction outlook weigh on the stock.
• B of A Securities lowered McKesson's price target to $1000.00. • Seven insider sales occurred in the past six months with no purchases. • UBS and T. Rowe Price reduced their McKesson holdings last quarter.
• Britt Vitalone retires as McKesson CFO after eight years. • Kenny Cheung appointed as new Executive Vice President and CFO. • Stock declined following the CFO transition announcement.


| Shareholders | Proportion |
|---|---|
| Vanguard Capital Management, LLC | 6.62% |
| BlackRock Institutional Trust Company, N.A. | 5.74% |
| State Street Investment Management (US) | 4.81% |
| MFS Investment Management | 2.81% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 48.66% |
| Investment Advisor/Hedge Fund | 32.95% |
| Pension Fund | 3.22% |
| Research Firm | 2.88% |
Related Instruments
Popular Instruments